Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (IKT)
Company Research
Source: GlobeNewswire
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments. “During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We expect to initiate our Phase 2b clinical study of IKT-001, our prodrug of imatinib mesylate, in PAH during the fourth quarter of 2025.” Recent Developments: Advancement of IKT-001 as a therapy in PAH: The proposed Phase 2b IMPROVE-PAH trial is a multi-center, randomized, double-blind, placebo-controlled study of approximately 150 PAH participants. Participants under IMPROVE-PAH will be randomize
Show less
Read more
Impact Snapshot
Event Time:
IKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKT alerts
High impacting Inhibikase Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IKT
News
- Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.MarketBeat
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
IKT
Earnings
- 8/14/25 - Miss
IKT
Sec Filings
- 11/24/25 - Form 4
- 11/21/25 - Form 8-K
- 11/21/25 - Form 424B5
- IKT's page on the SEC website